Deck

Msscorps Co., Ltd. · 6830.TW · TWSE

Msscorps runs a Taiwan microscope shop for the chip industry, selling per-case material and failure analysis reports to TSMC-cluster fabs, OSATs and IC-design houses using high-end electron microscopes and proprietary techniques.

NT$780
Price (12 May 2026)
NT$40.4B
Market cap
NT$2.18B
Revenue (TTM)
536
Employees, 7 labs / 4 countries
Listed July 2021 at NT$169; bottomed NT$77 in late 2022; printed NT$1,000 in early May 2026 on the AI / silicon-photonics narrative, then gave back 20% in a week to NT$780.
2 · The tension

A 5× peer premium prices the FY26 margin snap-back as a near-certainty.

  • The premium. Msscorps trades at 50× trailing EV/EBITDA, 20× revenue, and 13× book against direct peer MA-Tek at 11×, 4×, and 4.5× — same Taiwan oligopoly, same down-cycle, MA-Tek delivered double the FY24 operating margin (13.9% vs 6.85%).
  • The bet behind it. Capex spiked from 34% of revenue in FY22 to 85% in FY24 (NT$1.67B); management guides FY26 capex back to ~17%. Gross margin halved from 40% to ~24% under the depreciation load, and is supposed to mechanically rebuild as the FY24-vintage fleet fills.
  • The decision date. Q2 FY26 earnings in early August is the first quarter where 1H operating margin tests the rebuild. Bull thesis needs OM ≥ 10% on revenue ≥ NT$600M; OM below 5% is the bear trigger for peer-multiple compression.
Pay full price for an unproven snap-back today, or wait three months for the August print and the end-2026 MSS HG launch to settle it.
3 · The hinge

The recovery curve cracked again in 1Q26 — Q2 in August is the print that resolves it.

  • The recovery. Quarterly gross margin rebuilt 13.2% → 25.7% → 25.3% → 28.6% across FY25 on monotonically rising revenue (NT$465M → NT$592M); operating margin clawed from −10.5% to +5.0%.
  • The reversion. 1Q26 broke the curve — revenue a record NT$579M (+24.5% YoY) but gross margin back to ~13% and EPS −NT$0.61, the second consecutive quarterly net loss after Q4 FY25 (Q3 FY25 was the only profitable quarter in the last five). The stock fell from NT$975 (5 May close) to NT$746 intraday on 13 May — a six-session drawdown.
  • What August settles. A Q2 print at GM ≥ 25% and OM ≥ 10% reads 1Q26 as an anomaly; another GM-13 print sustains the bear's argument that better-executing MA-Tek delivers the same playbook at one-fifth the multiple.
1Q26 is either a step-back inside an uneven ramp, or the leading edge of a stalled utilisation cycle. The August print resolves which.
4 · Money picture

Cash flow held while GAAP earnings fell off a cliff — the cliff was depreciation; the watch item is the next financing event.

NT$743M
Operating cash flow FY25 NT$663M in FY22, +12% across the GAAP collapse
(NT$439M)
Free cash flow FY25 capex 159% of OCF
47%
Debt to assets FY24 from 33% in FY22; first-ever convertible bond
NT$500M
FY26 capex guide down from NT$1.67B in FY24

Operating cash flow grew NT$663M → NT$743M across FY22–FY25 even as net income swung from a NT$288M profit to a NT$37M loss — the GAAP collapse is depreciation, with a clean forensic scorecard (accruals ratio −12.4%, CFO/NI 3.28×, zero red flags). But cumulative FY24–25 capex of NT$2.85B forced a NT$471M convertible bond, a 78% dividend cut, and pushed the current ratio from 3.27 to 1.09. If FY26 capex actually drops to NT$500M and quarterly margins hold, FCF flips positive and FY27 EBITDA roughly doubles. If utilisation slips, the next financing event is plausibly an equity raise into a stock the market has bid to 13× book.

5 · The variant

Three things the consensus quote on this name misreads.

  • Wrong-cycle peer compare. MA-Tek absorbed its capex wave in FY21–22 and has been harvesting since (capex intensity ~30%, OM band 11.5–18.7%); Msscorps' capex intensity ran 34% → 55% → 85% across FY22–24 and only just turned. The bear's 5× peer-multiple anchor compares a harvester to a builder — the cleaner test is Msscorps FY27 normalised against MA-Tek FY24, decided in two prints.
  • MSS HG is equipment, not a story slide. The CPO inspection platform launching end-2026 carries disclosed pricing of NT$40–100M per unit and is backed by an offensive NT$200M patent suit (Enli, March 2026) — the legal posture of equipment IP, not service IP. Even ten units in FY27 would add NT$400M–1B at semiconductor-equipment-grade margins; no analyst has put that line in a model.
  • The "3.7× sole broker target" is consensus by vacuum. Masterlink's NT$204 target was set on 2 January 2026 — before the MSS HG unveil, the Enli suit, the 4Q25 GM print, and the named-customer disclosure. The right description is "no consensus exists," not "consensus is far below the tape."
The variant view is not cheap. It is that the bear's anchor benchmark is the wrong benchmark, and the bear's lone-target headline is not consensus at all.
6 · Bull & Bear

Lean watchlist — bear evidence is heavier today, but every disconfirming event arrives inside six months.

  • For. Operating cash flow grew NT$663M → NT$743M across a GAAP collapse from NT$288M profit to a NT$37M loss; the cash-generating service base is intact and the depreciation drag is mechanically front-loaded.
  • For. 4Q25 gross margin recovered to 28.6% on record revenue; an offensive NT$200M patent suit confirms the CPO IR-leakage IP is treated as a product-grade asset; and Apple/Nvidia/AMAT/Lam are named (in trade press, not yet in filings) at MSS USA.
  • Against. 50× trailing EV/EBITDA against a direct peer at 11× that delivered double the operating margin through the same tool wave; FCF was −NT$439M in FY25, debt-to-assets jumped to 47%, the dividend was cut 78%, and the "functional monopoly" claim rests on one third-party citation.
  • Against. Top-2 customers stay anonymous at 44% of revenue; founder is Chairman, President and CEO with no Lead Independent Director; the chairman's son was placed on the board and given the MSS USA CEO seat within three years of grad school; FY24 executive pay ran at 66% of net profit.
View flips to Lean Long on a Q2 FY26 print of GM ≥ 25% paired with a named hyperscaler. Flips to Avoid if Q2 GM is sub-25% with revenue decelerating below the +30% guide.

Watchlist to re-rate: Q2 FY26 quarterly operating margin (early August), MSS HG first commercial order (end-2026 to early-2027), monthly TWSE revenue tape vs the MA-Tek + iST trio average each tenth of the month.